nach oben

International Journal of Clinical Oncology

Erschienen in:

01.06.2013 | Original Article

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

verfasst von: Kyoichi Kaira, Toshiaki Takahashi, Haruyasu Murakami, Takehito Shukuya, Hirotsugu Kenmotsu, Akira Ono, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura, Masahiro Endo, Haruhiko Kondo, Takashi Nakajima, Nobuyuki Yamamoto

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study is to evaluate whether class III β-tubulin (TUBB3) expression could predict progression-free survival or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with taxene-based chemotherapy.

Methods

Immunohistochemistal staining was used to examine the expression of TUBB3 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy against recurrent tumors after curative resections. Excision repair cross-complementation group 1, breast cancer susceptibility gene 1, vascular endothelial growth factor, Ki-67, CD34, and p53 were also correlated with clinical features and outcome after treatment.

Results

Of the 56 patients enrolled in the study, 29 were treated by carboplatin plus paclitaxel as first-line treatment, and 24 patients received docetaxel monotherapy as second- or third-line treatment. A positive TUBB3 expression is closely associated with a poor response to taxane-based chemotherapy. TUBB3 expression was an independent prognostic factor for predicting poor progression-free survival after docetaxel administration. However, TUBB3 expression could not predict outcome after carboplatin plus paclitaxel treatment. The other biomarkers tested were not independent prognostic factors for predicting outcome after taxane-based chemotherapy.

Conclusion

TUBB3 expression is associated with resistance to taxane-based chemotherapy and is an independent prognostic factor for predicting poor progression-free survival after docetaxel treatment alone. TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease.

Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630PubMed

Kaira K, Yamamoto N (2010) Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4:1–9CrossRef

Jordan MA, Wilson L (2001) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265CrossRef

Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, XRCC1, and β III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478–483PubMedCrossRef

Seve P, Reiman T, Dumontet C (2010) The role of βIII-tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136–143

Azuma K, Sasada K, Kawahara A et al (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333PubMedCrossRef

Rosell R, Scagliotti G, Danenberg KD et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene 22:3548–3552PubMedCrossRef

Dumontet C, Isaac S, Souquet PJ et al (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30PubMed

Seve P, Issac S, Tredan O et al (2005) Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481–5486PubMedCrossRef

10.

Seve P, Mackey J, Issac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007PubMedCrossRef

11.

Hayashi Y, Kuriyama H, Umezu H et al (2009) Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 48:203–208PubMedCrossRef

12.

Volker M, Mone MJ, Kamakar P et al (2001) Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8:213–224PubMedCrossRef

13.

Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef

14.

Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef

15.

Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808PubMedCrossRef

16.

Mountain CF (1997) Revision in the International System for Staging Lung Cancer. Chest 11:1710–1717CrossRef

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef

18.

Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5:320–325PubMedCrossRef

19.

Skov BG, Holm B, Erreboe A et al (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5:453–459PubMedCrossRef

20.

Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[¹⁸F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753PubMedCrossRef

21.

Kaira K, Oriuchi N, Shimizu K et al (2008) Evaluation of thoracic tumors with ¹⁸F-FMT and ¹⁸F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152–1160CrossRef

22.

Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742–748PubMedCrossRef

23.

Davies AM, Lara PN Jr, Mack PC et al (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4:553–565PubMedCrossRef

24.

Maio MD, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843PubMedCrossRef

25.

Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343PubMedCrossRef

26.

Vilmar A, Santoni-Rugiu E, Sørensen JB (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 13:1554–1562CrossRef

27.

Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521PubMedCrossRef

Titel: The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy
verfasst von: Kyoichi Kaira
Toshiaki Takahashi
Haruyasu Murakami
Takehito Shukuya
Hirotsugu Kenmotsu
Akira Ono
Tateaki Naito
Asuka Tsuya
Yukiko Nakamura
Masahiro Endo
Haruhiko Kondo
Takashi Nakajima
Nobuyuki Yamamoto
Publikationsdatum: 01.06.2013
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 3/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0386-8

Springer Medizin

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy